prophylactic effect and QOL analysis of in gargling with pilocarpine and polaprezinc for radiation-induced xerostomia

prophylactic effect and QOL analysis of in gargling with pilocarpine and polaprezinc for radiation-induced xerostomia - prophylactic effect and QOL analysis of in gargling with pilocarpine and polaprezinc for radiation-induced xerostomia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019179

Enrollment

Registered

2015-10-01

Start date

2015-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

gargling with pirocarpine and polaprezinc since starting radiotherapy to 1 month after radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who will be treated with radiotherapy for head and neck cancer 2. mean irradiated dose for protid grand is more than 20 Gy 3. PS(ECOG)=0-2

Exclusion criteria

Exclusion criteria: 1. severe complication 2. without informed consent

Design outcomes

Primary

Measure	Time frame
alteration in oral QOL score, saliva production and gustatory sense.	—

Countries

Japan

Contacts

Public ContactKeiichi Jingu

Tohoku university graduate school of medicine Department of Radiuation Oncology

kjingu-jr@rad.med.tohoku.ac.jp+81-22-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026